Clinical Trials Directory

Trials / Completed

CompletedNCT00002620

Radiation Therapy in Treating Patients With Brain Cancer

EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
212 (estimated)
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC · Network
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for patients with anaplastic astrocytomas. PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy in treating patients with anaplastic astrocytomas.

Detailed description

OBJECTIVES: I. Compare the disease-free interval and survival in patients with supratentorial malignant brain gliomas randomized to radiotherapy alone vs. radiotherapy plus radiosensitization with mitolactol (DBD) followed by DBD and carmustine. OUTLINE: Randomized study. Group I: Radiotherapy. External-beam cranial irradiation with megavoltage equipment. Group II: Radiotherapy with Radiosensitization followed by Maintenance Chemotherapy. Radiotherapy as in Group I; with Mitolactol, DBD, NSC-104800; followed by DBD; Carmustine, BCNU, NSC-409962. PROJECTED ACCRUAL: A total of 212 patients will be entered over more than 3 years.

Conditions

Interventions

TypeNameDescription
DRUGcarmustine
DRUGchemotherapy
DRUGmitolactol
RADIATIONlow-LET cobalt-60 gamma ray therapy
RADIATIONlow-LET photon therapy

Timeline

Start date
1994-11-01
Primary completion
2000-06-01
First posted
2004-07-19
Last updated
2012-07-02

Locations

14 sites across 8 countries: Austria, Belgium, Germany, Italy, Netherlands, Portugal, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT00002620. Inclusion in this directory is not an endorsement.